{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:35:42Z","timestamp":1792121742918,"version":"4.4.0"},"reference-count":77,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>KMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2A-r B-ALL) is an aggressive subtype of leukemia, characterized by high relapse rates, therapy resistance, and poor prognosis. Although CD19-targeted immunotherapies have significantly benefited patients with relapsed\/refractory disease, relapses remain common and long-term survival is especially poor in patients with KMT2A-r B-ALL. We recently identified the membrane-bound proteoglycan, neuron-glial antigen 2 (NG2; CSPG4), as a direct transcriptional target of KMT2A fusions, with its expression associated with poor prognosis, early relapse, and glucocorticoid resistance in KMT2A-r B-ALL. However, the molecular mechanism underlying the aggressiveness of KMT2A-r B-ALL remains poorly understood. Here, we identify the \u03b14 integrin subunit (ITGA4) and NG2 as a key biological axis contributing to leukemic aggressiveness. NG2 expression promotes proliferation and migration of KMT2A-r B-ALL cells, and it is associated with Rho GTPase activity in an ITGA4-dependent manner. In vivo studies using immunodeficient mice demonstrated that ITGA4 and NG2 cooperate to promote leukemia progression, as combined genetic ablation of both genes significantly delayed disease onset and prolonged survival. Notably, natalizumab (NTZ), a clinically approved monoclonal antibody targeting ITGA4, delayed leukemia progression and potentiated the efficacy of standard-of-care chemotherapy in patient-derived KMT2A-r B-ALL xenograft models. Collectively, our findings define a novel ITGA4-NG2 signaling axis that drives the aggressiveness of KMT2A-r B-ALL and support the repurpose of NTZ as an adjuvant therapeutic strategy for this high-risk leukemia subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031693","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:42:04Z","timestamp":1782387724000},"page":"2013-2028","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["The NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-0854","authenticated-orcid":false,"given":"Alba","family":"Rubio-Gayarre","sequence":"first","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"2Centre for Genomics and Oncological Research, Pfizer\/University of Granada\/Andalusian Regional Government, Parque Tecnol\u00f3gico de la Salud, Granada, Spain"},{"name":"3Department of Physiology, University of Granada, Granada, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-4701","authenticated-orcid":false,"given":"Meritxell","family":"Vinyoles","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-9698","authenticated-orcid":false,"given":"Juan Ram\u00f3n","family":"Tejedor","sequence":"additional","affiliation":[{"name":"5Fundaci\u00f3n para la Investigaci\u00f3n Biosanitaria de Asturias, Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias, Instituto Universitario de Oncolog\u00eda de Asturias, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Asturias, Spain"},{"name":"6Nanomaterials and Nanotechnology Research Center, Spanish National Research Council, University of Oviedo, Oviedo, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-2460","authenticated-orcid":false,"given":"Mercedes","family":"Guerrero-Murillo","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-1080","authenticated-orcid":false,"given":"Narc\u00eds","family":"Fern\u00e1ndez-Fuentes","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-3432","authenticated-orcid":false,"given":"Rita","family":"Caracuel-Peramos","sequence":"additional","affiliation":[{"name":"2Centre for Genomics and Oncological Research, Pfizer\/University of Granada\/Andalusian Regional Government, Parque Tecnol\u00f3gico de la Salud, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Carmen","family":"Plaza-Calonge","sequence":"additional","affiliation":[{"name":"2Centre for Genomics and Oncological Research, Pfizer\/University of Granada\/Andalusian Regional Government, Parque Tecnol\u00f3gico de la Salud, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7514-260X","authenticated-orcid":false,"given":"Alba","family":"Mart\u00ednez-Moreno","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7324-5234","authenticated-orcid":false,"given":"Heleia","family":"Roca-Ho","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Petazzi","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3160-5562","authenticated-orcid":false,"given":"Alba","family":"Pa\u00f1ella-Alf\u00e9rez","sequence":"additional","affiliation":[{"name":"2Centre for Genomics and Oncological Research, Pfizer\/University of Granada\/Andalusian Regional Government, Parque Tecnol\u00f3gico de la Salud, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4056-0743","authenticated-orcid":false,"given":"Angela","family":"Meseguer-Giron","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Panelli","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-272X","authenticated-orcid":false,"given":"Kirsten S.","family":"Vrenken","sequence":"additional","affiliation":[{"name":"7Princess M\u00e0xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario F.","family":"Fraga","sequence":"additional","affiliation":[{"name":"5Fundaci\u00f3n para la Investigaci\u00f3n Biosanitaria de Asturias, Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias, Instituto Universitario de Oncolog\u00eda de Asturias, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Asturias, Spain"},{"name":"6Nanomaterials and Nanotechnology Research Center, Spanish National Research Council, University of Oviedo, Oviedo, Asturias, Spain"},{"name":"8Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Oviedo, Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Leoz-Allegretti","sequence":"additional","affiliation":[{"name":"9Hematology Department, La Santa Creu i Sant Pau Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9085-3327","authenticated-orcid":false,"given":"Carlos","family":"Palacio-Garcia","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Velasco","sequence":"additional","affiliation":[{"name":"11Department of Pediatric Oncology and Hematology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"12Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Autonomous University of Barcelona, Barcelona, Spain"},{"name":"13Childhood Cancer and Blood Disorders Research Group, Vall d'Hebron Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4881-9440","authenticated-orcid":false,"given":"Jose Luis","family":"Fuster","sequence":"additional","affiliation":[{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"14Department of Pediatric Oncohematology, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain"},{"name":"15Instituto Murciano de Investigaci\u00f3n Biosanitaria, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4986-1656","authenticated-orcid":false,"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[{"name":"7Princess M\u00e0xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-7029","authenticated-orcid":false,"given":"Juan Carlos","family":"Rodr\u00edguez-Manzaneque","sequence":"additional","affiliation":[{"name":"2Centre for Genomics and Oncological Research, Pfizer\/University of Granada\/Andalusian Regional Government, Parque Tecnol\u00f3gico de la Salud, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9398-6072","authenticated-orcid":false,"given":"Xos\u00e9 R.","family":"Bustelo","sequence":"additional","affiliation":[{"name":"16Centro de Investigaci\u00f3n del C\u00e1ncer, Centro Superior de Investigaciones Cient\u00edficas-University of Salamanca, Salamanca, Spain"},{"name":"17Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Centro Superior de Investigaciones Cient\u00edficas-University of Salamanca, Salamanca, Spain"},{"name":"18Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-0187","authenticated-orcid":false,"given":"Javier","family":"Robles-Valero","sequence":"additional","affiliation":[{"name":"16Centro de Investigaci\u00f3n del C\u00e1ncer, Centro Superior de Investigaciones Cient\u00edficas-University of Salamanca, Salamanca, Spain"},{"name":"17Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Centro Superior de Investigaciones Cient\u00edficas-University of Salamanca, Salamanca, Spain"},{"name":"18Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Menendez","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"18Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"19Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"20Instituci\u00f2 Catalana de Recerca i Estudis Avan\u00e7ats, Barcelona, Spain"},{"name":"21Paediatric Haematologic Malignancies Research Programme, Josep Carreras Leukaemia Research Institute, Institut de Recerca Sant Joan de D\u00e9u, Pediatric Cancer Center Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1442-6216","authenticated-orcid":false,"given":"Clara","family":"Bueno","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"18Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Lopez-Millan","sequence":"additional","affiliation":[{"name":"1Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain"},{"name":"2Centre for Genomics and Oncological Research, Pfizer\/University of Granada\/Andalusian Regional Government, Parque Tecnol\u00f3gico de la Salud, Granada, Spain"},{"name":"3Department of Physiology, University of Granada, Granada, Spain"},{"name":"4Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud de la Red Espa\u00f1ola de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2026101511215850200_bib1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.2287","article-title":"The pediatric cancer genome project","volume":"44","author":"Downing","year":"2012","journal-title":"Nat Genet"},{"issue":"6","key":"2026101511215850200_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2026101511215850200_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2403283","article-title":"Clinical significant of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse","volume":"18","author":"Coustan-Smith","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"2026101511215850200_bib4","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9583","key":"2026101511215850200_bib5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"2026101511215850200_bib6","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2015.246","article-title":"Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol","volume":"30","author":"Driessen","year":"2016","journal-title":"Leukemia"},{"issue":"25","key":"2026101511215850200_bib7","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026101511215850200_bib8","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3324\/haematol.2024.285642","article-title":"KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges","volume":"110","author":"Stutterheim","year":"2025","journal-title":"Haematologica"},{"issue":"16","key":"2026101511215850200_bib9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"2026101511215850200_bib10","doi-asserted-by":"crossref","first-page":"20406207231201454","DOI":"10.1177\/20406207231201454","article-title":"Survival outcomes in patients with relapsed\/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab","volume":"14","author":"Kantarjian","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"17","key":"2026101511215850200_bib11","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"2026101511215850200_bib12","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children\u2019s oncology group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026101511215850200_bib13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/jcpt.13741","article-title":"The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials","volume":"47","author":"Mocquot","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"2026101511215850200_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"2026101511215850200_bib15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026101511215850200_bib16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1","article-title":"Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse - the Children\u2019s Cancer Group experience","volume":"82","author":"Gaynon","year":"1998","journal-title":"Cancer"},{"issue":"6","key":"2026101511215850200_bib17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ccell.2016.11.002","article-title":"Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia","volume":"30","author":"Ebinger","year":"2016","journal-title":"Cancer Cell"},{"issue":"3","key":"2026101511215850200_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3324\/haematol.11796","article-title":"Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells","volume":"93","author":"Mahlknecht","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2026101511215850200_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct Target Ther 2022"},{"issue":"4","key":"2026101511215850200_bib20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12185-010-0555-3","article-title":"Essential roles of VLA-4 in the hematopoietic system","volume":"91","author":"Imai","year":"2010","journal-title":"Int J Hematol"},{"issue":"10","key":"2026101511215850200_bib21","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2012-01-406272","article-title":"Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy","volume":"121","author":"Hsieh","year":"2013","journal-title":"Blood"},{"issue":"17","key":"2026101511215850200_bib22","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2013-06-511527","article-title":"Reciprocal leukemia-stroma VCAM-1\/VLA-4-dependent activation of NF-\u03baB mediates chemoresistance","volume":"123","author":"Jacamo","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2026101511215850200_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026101511215850200_bib24","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2023022050","article-title":"NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression","volume":"144","author":"Lopez-Millan","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026101511215850200_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2017.294","article-title":"NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL","volume":"32","author":"Prieto","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"2026101511215850200_bib26","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41375-018-0353-0","article-title":"NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia","volume":"33","author":"Lopez-Millan","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"2026101511215850200_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1756285608101861","article-title":"Natalizumab in the treatment of multiple sclerosis","volume":"2","author":"Yaldizli","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"2026101511215850200_bib28","first-page":"CD006097","article-title":"Natalizumab for induction of remission in Crohn\u2019s disease","volume":"8","author":"Nelson","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"2026101511215850200_bib29","doi-asserted-by":"crossref","first-page":"e138833","DOI":"10.1172\/JCI138833","article-title":"Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia","volume":"131","author":"Tejedor","year":"2021","journal-title":"J Clin Invest"},{"issue":"3","key":"2026101511215850200_bib30","first-page":"313","article-title":"Impaired condensin complex and aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-Cell ALL","volume":"136","author":"Molina","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2026101511215850200_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1477460","article-title":"IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC \/ Idarubicin activity in preclinical models of non del5q \/ 5q- AML","volume":"7","author":"Lopez-Millan","year":"2018","journal-title":"Oncoimmunology"},{"issue":"7","key":"2026101511215850200_bib32","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3324\/haematol.2012.079244","article-title":"Cord blood-derived CD34+ hematopoietic cells with low mitochondrial mass are enriched in hematopoietic repopulating stem cell function","volume":"98","author":"Romero-Moya","year":"2013","journal-title":"Haematologica"},{"key":"2026101511215850200_bib33","first-page":"161","article-title":"In vitro and in vivo assays of B-lymphocyte migration","volume":"271","author":"Moratz","year":"2004","journal-title":"Methods Mol Biol"},{"issue":"3","key":"2026101511215850200_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/scd.2015.0309","article-title":"Intra-bone marrow transplantation confers superior multilineage engraftment of murine aorta-gonad mesonephros cells over intravenous transplantation","volume":"25","author":"Sanjuan-Pla","year":"2016","journal-title":"Stem Cells Dev"},{"issue":"4","key":"2026101511215850200_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/cell.2022.0025","article-title":"Signaling pathways and protein-protein interaction of vimentin in invasive and migration cells: a review","volume":"24","author":"Karoii","year":"2022","journal-title":"Cell Reprogram"},{"issue":"4","key":"2026101511215850200_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MOH.0b013e328362370f","article-title":"Galectins in hematological malignancies","volume":"20","author":"Giordano","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"2026101511215850200_bib37","doi-asserted-by":"crossref","first-page":"1354992","DOI":"10.3389\/fimmu.2024.1354992","article-title":"CD44: a cancer stem cell marker and therapeutic target in leukemia treatment","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"2026101511215850200_bib38","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3389\/fonc.2020.01672","article-title":"Targeting CXCR4 in AML and ALL","volume":"10","author":"Cancilla","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"2026101511215850200_bib39","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.3390\/ijms21062206","article-title":"VLA-4 expression and activation in B cell malignancies: functional and clinical aspects","volume":"21","author":"H\u00e4rzschel","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026101511215850200_bib40","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1046\/j.1365-2141.1998.00899.x","article-title":"VLA-4 is involved in the engraftment of the human pre-B acute lymphoblastic leukaemia cell line NALM-6 in SCID mice","volume":"102","author":"Filshie","year":"1998","journal-title":"Br J Haematol"},{"issue":"6","key":"2026101511215850200_bib41","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2018.206375","article-title":"Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis","volume":"104","author":"Agraz-Doblas","year":"2019","journal-title":"Haematologica"},{"issue":"Pt 19","key":"2026101511215850200_bib42","first-page":"4292","article-title":"Coronin-1C and RCC2 guide mesenchymal migration by trafficking Rac1 and controlling GEF exposure","volume":"127","author":"Williamson","year":"2014","journal-title":"J Cell Sci"},{"issue":"25","key":"2026101511215850200_bib43","doi-asserted-by":"crossref","first-page":"15437","DOI":"10.1074\/jbc.M115.640367","article-title":"Coronin-1C protein and caveolin protein provide constitutive and inducible mechanisms of rac1 protein trafficking","volume":"290","author":"Williamson","year":"2015","journal-title":"J Biol Chem"},{"issue":"2","key":"2026101511215850200_bib44","doi-asserted-by":"crossref","first-page":"101579","DOI":"10.1016\/j.jbc.2022.101579","article-title":"The Rho guanine nucleotide exchange factor PLEKHG1 is activated by interaction with and phosphorylation by Src family kinase member FYN","volume":"298","author":"Nakano","year":"2022","journal-title":"J Biol Chem"},{"issue":"36","key":"2026101511215850200_bib45","doi-asserted-by":"crossref","first-page":"23995","DOI":"10.1074\/jbc.M109.024398","article-title":"Dynamin2 GTPase and cortactin remodel actin filaments","volume":"284","author":"Mooren","year":"2009","journal-title":"J Biol Chem"},{"issue":"15","key":"2026101511215850200_bib46","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020008738","article-title":"RhoG deficiency abrogates cytotoxicity of human lymphocytes and causes hemophagocytic lymphohistiocytosis","volume":"137","author":"Kalinichenko","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026101511215850200_bib47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1083\/jcb.200612053","article-title":"RhoG regulates endothelial apical cup assembly downstream from ICAM1 engagement and is involved in leukocyte trans-endothelial migration","volume":"178","author":"Van Buul","year":"2007","journal-title":"J Cell Biol"},{"issue":"1","key":"2026101511215850200_bib48","doi-asserted-by":"crossref","first-page":"111824","DOI":"10.1016\/j.yexcr.2020.111824","article-title":"Rho GTPases and related signaling complexes in cell migration and invasion","volume":"388","author":"Guan","year":"2020","journal-title":"Exp Cell Res"},{"key":"2026101511215850200_bib49","doi-asserted-by":"crossref","first-page":"e27958","DOI":"10.4161\/sgtp.27958","article-title":"The on-off relationship of Rho and Rac during integrin-mediated adhesion and cell migration","volume":"5","author":"Lawson","year":"2014","journal-title":"Small GTPases"},{"issue":"2","key":"2026101511215850200_bib50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41580-024-00777-1","article-title":"The role and regulation of integrins in cell migration and invasion","volume":"26","author":"Chastney","year":"2025","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"2026101511215850200_bib51","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.onc.1206116","article-title":"RhoG regulates gene expression and the actin cytoskeleton in lymphocytes","volume":"22","author":"Vigorito","year":"2003","journal-title":"Oncogene"},{"issue":"1629","key":"2026101511215850200_bib52","doi-asserted-by":"crossref","first-page":"20130013","DOI":"10.1098\/rstb.2013.0013","article-title":"Roles of Rho GTPases in leucocyte and leukaemia cell transendothelial migration","volume":"368","author":"Infante","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2026101511215850200_bib53","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"2026101511215850200_bib54","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.3390\/ijms19092724","article-title":"The significance of chondroitin sulfate proteoglycan 4 (CSPG4) in human gliomas","volume":"19","author":"Schiffer","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2026101511215850200_bib55","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.3390\/cancers14225564","article-title":"Chondroitin sulfate proteoglycan 4 as a marker for aggressive squamous cell carcinoma","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026101511215850200_bib56","doi-asserted-by":"crossref","first-page":"939166","DOI":"10.3389\/fonc.2022.939166","article-title":"Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: a potential target for antibody-based immunotherapy","volume":"12","author":"Nota","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"2026101511215850200_bib57","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbrc.2013.10.093","article-title":"High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer","volume":"441","author":"Hsu","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"2026101511215850200_bib58","doi-asserted-by":"crossref","first-page":"101318","DOI":"10.1016\/j.tranon.2021.101318","article-title":"Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation","volume":"16","author":"Yang","year":"2022","journal-title":"Transl Oncol"},{"issue":"3","key":"2026101511215850200_bib59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4161\/cam.2.3.6279","article-title":"A role for the NG2 proteoglycan in glioma progression","volume":"2","author":"Stallcup","year":"2008","journal-title":"Cell Adh Migr"},{"issue":"3","key":"2026101511215850200_bib60","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3892\/ijo.2021.5250","article-title":"A chondroitin sulfate proteoglycan 4-specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model","volume":"59","author":"Uranowska","year":"2021","journal-title":"Int J Oncol"},{"issue":"4","key":"2026101511215850200_bib61","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/CMR.0000000000000574","article-title":"Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain","volume":"29","author":"Yang","year":"2019","journal-title":"Melanoma Res"},{"issue":"19","key":"2026101511215850200_bib62","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/0008-5472.CAN-08-4626","article-title":"Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"issue":"53","key":"2026101511215850200_bib63","doi-asserted-by":"crossref","first-page":"55262","DOI":"10.1074\/jbc.M411045200","article-title":"Phosphorylation of NG2 proteoglycan by protein kinase C-\u03b1 regulates polarized membrane distribution and cell motility","volume":"279","author":"Makagiansar","year":"2004","journal-title":"J Biol Chem"},{"issue":"39","key":"2026101511215850200_bib64","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1038\/onc.2008.157","article-title":"The progenitor cell marker NG2\/MPG promotes chemoresistance by activation of integrin-dependent PI3K\/Akt signaling","volume":"27","author":"Chekenya","year":"2008","journal-title":"Oncogene"},{"issue":"10","key":"2026101511215850200_bib65","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1074\/jbc.273.10.5955","article-title":"A role of chondroitin sulfate glycosaminoglycan binding site in \u03b14\u03b21 integrin-mediated melanoma cell adhesion","volume":"273","author":"Iida","year":"1998","journal-title":"J Biol Chem"},{"issue":"2","key":"2026101511215850200_bib66","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1083\/jcb.118.2.431","article-title":"Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin","volume":"118","author":"Iida","year":"1992","journal-title":"J Cell Biol"},{"issue":"6","key":"2026101511215850200_bib67","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1083\/jcb.200403174","article-title":"Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms","volume":"165","author":"Yang","year":"2004","journal-title":"J Cell Biol"},{"issue":"5","key":"2026101511215850200_bib68","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/cdd.2008.22","article-title":"NG2, a novel proapoptotic receptor, opposes integrin \u03b14 to mediate anoikis through PKCalpha-dependent suppression of FAK phosphorylation","volume":"15","author":"Joo","year":"2008","journal-title":"Cell Death Differ"},{"issue":"8","key":"2026101511215850200_bib69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/70302","article-title":"Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas","volume":"1","author":"Eisenmann","year":"1999","journal-title":"Nat Cell Biol"},{"issue":"9","key":"2026101511215850200_bib70","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/cancers10090325","article-title":"G9a correlates with VLA-4 integrin and influences the migration of childhood acute lymphoblastic leukemia cells","volume":"10","author":"Madrazo","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2026101511215850200_bib71","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm909","article-title":"Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia","volume":"9","author":"Matsunaga","year":"2003","journal-title":"Nat Med"},{"issue":"21","key":"2026101511215850200_bib72","first-page":"3944","article-title":"VLA4 blockade in acute myeloid leukemia","volume":"122","author":"Hsieh","year":"2013","journal-title":"Am Soc Hematol"},{"issue":"6","key":"2026101511215850200_bib73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-020-0331-4","article-title":"Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment","volume":"10","author":"Nair-Gupta","year":"2020","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026101511215850200_bib74","doi-asserted-by":"crossref","first-page":"e52208","DOI":"10.1371\/journal.pone.0052208","article-title":"Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis","volume":"7","author":"Benkert","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"2026101511215850200_bib75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40164-025-00668-x","article-title":"MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting","volume":"14","author":"Sun","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 1","key":"2026101511215850200_bib76","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations [abstract]","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026101511215850200_bib77","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2024-194384","article-title":"Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia [abstract]","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/16\/2013\/2594991\/blood_bld-2025-031693-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/16\/2013\/2594991\/blood_bld-2025-031693-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:22:11Z","timestamp":1792077731000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/16\/2013\/569304\/The-NG2-ITGA4-axis-regulates-Rho-GTPases-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":77,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031693","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,10,15]]}}}